Journal article icon

Journal article

TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism

Abstract:

Background Transforming growth factor-β (TGFβ) is emerging as a promising target for cancer therapy, given its ability to promote progression of advanced tumors and to suppress anti-tumor immune responses. However, TGFβ also plays multiple roles in normal tissues, particularly during organogenesis, raising toxicity concerns about TGFβ blockade. Dose-limiting cardiovascular toxicity was observed, possibly due to the blockade of all three TGFβ isoforms. The dominant isoform in tumors is TGFβ1, ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1136/jitc-2020-001798

Authors


More by this author
Role:
Author
ORCID:
0000-0001-6761-6836
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Oxford Ludwig Institute
Role:
Author
ORCID:
0000-0002-4995-3270
Publisher:
BMJ Publishing Group Publisher's website
Journal:
Journal for ImmunoTherapy of Cancer Journal website
Volume:
9
Issue:
2
Article number:
e001798
Place of publication:
England
Publication date:
2021-02-26
Acceptance date:
2021-01-06
DOI:
ISSN:
2051-1426
Pmid:
33637600
Language:
English
Keywords:
Pubs id:
1163936
Local pid:
pubs:1163936
Deposit date:
2021-05-18

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP